Colorectal News and Research

RSS

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

A Yorkshire Cancer Research scientist has earned himself a national medical award for helping pioneer life-saving surgical improvements to the way tumours are removed from colon cancer patients.

18 Nov 2010

Uniting announces recipient of 'Caine Halter Hope Now Award for Lung Cancer Research'

Uniting Against Lung Cancer (Uniting) announces the "Caine Halter Hope Now Award for Lung Cancer Research."

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

EDP Biotech introduces new blood test for detecting early-stage colon cancer at Medica trade fair

The future of colon cancer screening may be surprisingly simple. ColoMarker, an innovative blood test to detect the early stages of colon cancer is generating plenty of attention from a wide audience, including from some of the world's leading researchers in cancer biomarkers and gastrointestinal medicine.

18 Nov 2010

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

17 Nov 2010

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company's monoclonal antibody for colorectal and pancreatic cancer.

17 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Medicare open enrollment period starts today

Coming changes to Medicare will benefit some recipients but will make coverage more expensive for people with higher incomes. Thanks in part to this year's health care overhaul, everything from benefits and enrollment rules to the number of choices available will be affected beginning Jan. 1.

16 Nov 2010

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

16 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010

Screening colonoscopy rates for women do not increase when offered to be done by female endoscopists: Study

A new study from researchers in Colorado shows that women offered a female endoscopist were not more likely to undergo a screening colonoscopy than those who were not offered this choice. Past surveys have shown preferences for female endoscopists seem to be common among women. In this study, a patient outreach program failed to support the notion that rates of screening colonoscopy can be increased by offering women the option of a screening colonoscopy performed by a female endoscopist.

12 Nov 2010

SU2C to receive second CLIO Healthcare Award

The CLIO Healthcare Awards will present its second annual honorary award, to Stand Up To Cancer (SU2C), on November 12th, 2010. This dedicated award celebrates an organization or individual for excellence in healthcare communications and for contributing to the improvement of public health.

12 Nov 2010

Colonoscopy screening could prevent bowel cancer in nearly 99 000 German patients

By the end of this year, colonoscopy screening will have prevented bowel cancer in approximately 99 000 people since it was introduced in Germany. This is the result obtained by Hermann Brenner of the German Cancer Research Center in Heidelberg and his co-authors in their interim assessment conducted eight years after the procedure was added to the German cancer screening program.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Exact Sciences completes underwritten public offering

Exact Sciences Corp. today announced that it has completed its previously announced underwritten public offering of common stock at a price of $6.00 per share.

10 Nov 2010

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Neogenix awarded $488,958.50 grant under QTDP program

Neogenix Oncology, Inc. announced today that the company has been awarded two grants totaling $488,958.50, under the Qualifying Therapeutic Discovery Project Program. The two successful applications were for the company's h16C3 therapeutic antibody development program and the diagnostic biomarker development program for both their h16C3 and NPC-1C antibodies.

10 Nov 2010

Younger patients unable to cope with pain and emotional issues of cancer

Younger adult cancer patients have the most difficulty coping with the pain and emotional issues of cancer, in spite of their potentially better survival odds, according to a University of Michigan Health System study.

10 Nov 2010

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry [18:7966-7974, 2010] on the anticancer activity of quinoxalinyl-piperazine compounds.

9 Nov 2010

Colorectal News and Research

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

Uniting announces recipient of 'Caine Halter Hope Now Award for Lung Cancer Research'

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

EDP Biotech introduces new blood test for detecting early-stage colon cancer at Medica trade fair

Targeted therapies could treat a broad range of cancers: Research

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Study: EGFR inhibtion may help treat triple negative breast cancer

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Medicare open enrollment period starts today

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Screening colonoscopy rates for women do not increase when offered to be done by female endoscopists: Study

SU2C to receive second CLIO Healthcare Award

Colonoscopy screening could prevent bowel cancer in nearly 99 000 German patients

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Exact Sciences completes underwritten public offering

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Neogenix awarded $488,958.50 grant under QTDP program

Younger patients unable to cope with pain and emotional issues of cancer

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News